Palisade Bio Inc., a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, has appointed J.D. Finley Chief Executive Officer. Finley has been serving as interim CEO since October 2022.

“Since assuming the role of interim CEO, J.D. has demonstrated leadership and operational excellence as we have navigated through a difficult transitional period,” said James Neal, chairman of the Palisade Bio board of directors. “Palisade has never been stronger, and under his leadership the company has made significant progress in the clinical advancement of LB1148. We are pleased to officially name J.D. as CEO and we look forward to his continued contributions to the company.”

“Over the course of the last several months, we have worked diligently to identify a path to regulatory approval and commercialization,” said Finley. “We continue to believe there is great potential for LB1148 to transform the way physicians mitigate the risks of acute and chronic GI complications from surgery. I am grateful for the continued support of all our stakeholders and look forward to an exciting year ahead.”